Why Are Invitae's Shares Plunging Today?

  • Invitae Corp's NVTA Q3 sales increased 66% Y/Y to $114.4 million, missing the consensus Wall Street estimate of $126.55 million.
  • Invitae posted an 89% increase in billable test volume. The Company reported 296,000 billed tests in Q3 compared to 157,000 such tests during the year-ago period.
  • The Company's average cost per billable unit was $296 in Q3 compared to the $297 a year ago. The adjusted average cost per unit was $249 in the quarter.
  • The Company achieved an adjusted gross margin of 35.6% compared to 39% in Q3 FY20.
  • Invitae's net loss totaled $198.2 million compared to $102.9 million in Q3 2020. 
  • Adjusted EPS loss was $(0.81). On average, analysts had estimated a $(0.71) per share net loss.
  • Invitae ended the quarter with $921.6 million in cash and cash equivalents and $320.5 million in marketable securities.
  • Guidance: The Company lowered its FY21 revenue expectation to $450 million - $475 million, citing greater-than-expected seasonal impact in Q3.
  •  After Q2, the Company had projected FY 2021 revenues of $475 million - $500 million
  • Price Action: NVTA shares are down 11% at $23.37 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!